泰达生物发布中期业绩 股东应占亏损642.64万元 同比扩大55.86%

Group 1 - The company, 泰达生物, reported a revenue of RMB 226 million for the six months ending June 30, 2025, representing a year-on-year growth of 7.01% [1] - The loss attributable to shareholders increased to RMB 6.4264 million, which is a year-on-year expansion of 55.86% [1] - The loss per share was reported at 0.317 cents [1]